Cumberland Pharmaceuticals (CPIX) Accumulated Expenses (2011 - 2022)

Cumberland Pharmaceuticals has disclosed Accumulated Expenses across 12 years of filings, most recently posting $17.6 million for Q4 2022.

• Accumulated Expenses for Q4 2022 came in at $17.6 million, up 102.9% year-over-year; the trailing twelve-month figure through Dec 2022 was $17.6 million (up 102.9% YoY), and the FY2022 annual result was $17.6 million, up 102.9% from the prior year.
• Accumulated Expenses came in at $17.6 million for Q4 2022 at Cumberland Pharmaceuticals, up from $8.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $17.6 million in Q4 2022 to a low of $8.7 million in Q4 2021.
• The 5-year median for Accumulated Expenses is $11.3 million (2020), against an average of $13.1 million.
• Across the five-year window, Accumulated Expenses slumped 33.67% in 2019 and soared 102.9% in 2022, its largest moves.
• Cumberland Pharmaceuticals' Accumulated Expenses stood at $16.7 million in 2018, then plunged by 33.67% to $11.1 million in 2019, then rose by 1.53% to $11.3 million in 2020, then retreated by 22.98% to $8.7 million in 2021, then jumped by 102.9% to $17.6 million in 2022.
• The last three Accumulated Expenses figures came in at $17.6 million (Q4 2022), $8.7 million (Q4 2021), and $11.3 million (Q4 2020), per Business Quant data.